Short Interest in IGC Pharma, Inc. (NYSEAMERICAN:IGC) Rises By 46.3%

IGC Pharma, Inc. (NYSEAMERICAN:IGC) was the target of a large growth in short interest during the month of December. As of December 15th, there was short interest totaling 428,376 shares, a growth of 46.3% from the November 30th total of 292,751 shares. Currently, 0.6% of the company’s shares are short sold. Based on an average daily trading volume, of 707,283 shares, the short-interest ratio is presently 0.6 days. Based on an average daily trading volume, of 707,283 shares, the short-interest ratio is presently 0.6 days. Currently, 0.6% of the company’s shares are short sold.

IGC Pharma Trading Down 2.2%

IGC Pharma stock traded down $0.01 during mid-day trading on Wednesday, hitting $0.28. The company’s stock had a trading volume of 527,082 shares, compared to its average volume of 1,132,602. The business has a fifty day moving average price of $0.34. The company has a quick ratio of 0.89, a current ratio of 1.32 and a debt-to-equity ratio of 0.02. The firm has a market cap of $25.65 million, a price-to-earnings ratio of -3.95 and a beta of 0.24. IGC Pharma has a 1 year low of $0.25 and a 1 year high of $0.50.

IGC Pharma (NYSEAMERICAN:IGC) last issued its quarterly earnings data on Friday, November 14th. The company reported ($0.02) earnings per share (EPS) for the quarter. The company had revenue of $0.19 million during the quarter. IGC Pharma had a negative net margin of 583.91% and a negative return on equity of 96.54%.

About IGC Pharma

IGC Pharma, Inc, a clinical stage biotechnology company, engages in developing cannabinoid-based formulations for treating diseases and conditions, including Alzheimer’s disease, dysmenorrhea, premenstrual syndrome, and chronic pain. The company has two investigational drug assets targeting Alzheimer’s disease comprising IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer’s; and TGR-63 that is in pre-clinical development. It also markets Holief, a wellness brand that targets women experiencing premenstrual syndrome and menstrual cramps.